Evidence map›Paper›PMID 37644124›Full record

ArticleNature nanotechnology2023

The Cancer Moonshot, the role of in vitro models, model accuracy, and the need for validation.

Peter C Searson

Abstract read
In one paragraph

Article in Nature nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Pathway Analysis Interpretation in the Multi-Omic Era.Biotech (Basel (Switzerland)) · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Peter C SearsonInstitute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA. searson@jhu.edu.ORCID 0000-0002-5417-0828

Funding

Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Pei-Hsun wu · 2022 to 2026
$10.2M
Mechanisms of cerebrovascular barrier dysfunction caused by APP and PSEN1 mutations and amyloid beta exposureR01NS106008 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SEARSON, PETER C · 2019 to 2023
$1.9M
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brainR61HL154252 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HEIMAN, MYRIAM, SEARSON, PETER C · 2021 to 2022
$1.6M
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brainR33HL154252 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HEIMAN, MYRIAM, SEARSON, PETER C · 2023 to 2025
$1.3M
NCI NIH HHS U54 CA268083NHLBI NIH HHS R33 HL154252NINDS NIH HHS R01 NS106008U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R61HL154252U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS10600
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomedical ResearchNeoplasmsHumans

Identifiers

PMID37644124
PMCPMC12045577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.